Summary
"Cardiac Markers Pipeline Technology and Market Forecasts to 2015" report is an essential source of information and analysis on the global cardiac markers market. The report identifies the key trends shaping and driving the dynamism in the global cardiac markers market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global cardiac markers sector.
Scope
-This report analyzes a key segment within the in vitro diagnostics market with focus on the cardiovascular segment
-Annualized global cardiac markers market revenues data from 2001 to 2008, forecast forward for 7 years to 2015. Updated company shares data for 2008.
-Analysis and review of the key events and milestones that will impact the future of the global cardiac markers market. Each trend independently researched to provide qualitative analysis of what the implications on sectors are, and how are companies responding to these trends.
-Insightful review of key industry drivers, restraints and challenges which are likely to impact the global cardiac markers market in the long run.
-The report also covers information on the leading market players, the competitive landscape, and the leading pipeline products and technologies.Key companies covered include Abbott, Roche Diagnostics and Siemens Medical
-Comprehensive analysis of the most likely developments expected to bring a shift to the market positions of the leading manufacturers.
-The report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by's team of industry experts.
Reasons to buy
-Develop business strategies by understanding the trends shaping and driving the global cardiac markers market.
-Identify key players best positioned to take advantage of the emerging market opportunities by developing insight on the prevalent and anticipated competitive landscape.
-Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global cardiac markers market in future.
-Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
-Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
-Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
-Support your go/non-go dilemma by identifying the markets that are least competitive and present significant opportunities for innovation and growth.
-Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.
Table Of Contents
1.1 List of Tables 5
1.2 List of Figures 6
2 Cardiac Markers Pipeline Technology and Market Forecasts to 2015 7
2.1 Executive Summary 7
3 Cardiac Markers Technology Landscape 8
3.1 Cardiac Markers: Overview 8
3.2 Disease Background 9
3.3 Cardiac Markers Clinical Trials 10
3.3.1 Circulating Markers that Underlie the Transition from Compensated Hypertrophy to Heart Failure 10
3.3.2 Genetic-and Biological-Markers of Predisposition to Atherosclerosis: Leipzig-Heart Study (LE-Heart) 10
3.3.3 Discovery of New Circulating Biomarkers of Coronary Atherosclerosis 10
3.3.4 Assessment of New Biomarkers in the Management and Triage of Patients with Chest Pain and Suspicion of Non ST Elevation Acute Coronary Syndrome 11
4 Global Cardiac Markers Market 12
4.1 Market Overview 12
4.2 Cardiac Markers Market Dynamics 14
4.2.1 Market Drivers 14
4.2.1.1 Increasing Incidence of Cardiovascular Diseases Will Drive the Cardiac Markers Market 14
4.2.1.2 Increasing Awareness of Early Screening, Detection and Diagnosis Fuelling Growth 14
4.2.1.3 Point of Care (POC) Technologies will Drive Growth 14
4.2.2 Market Restraints 15
4.2.2.1 Low Reimbursement Rates will Hamper Growth 15
4.2.3 Technology Trends 15
4.2.4 Cross Country Comparison 17
5 Cardiac Markers Competitive Landscape 19
5.1 Abbott 19
5.2 Roche Diagnostics 19
5.3 Siemens Medical 19
5.4 Others 19
6 Cardiac Markers Pipeline Products 20
6.1 ARCHITECT MPO Assay 21
6.1.1 Product Status 21
6.1.2 Product Description 21
6.1.3 Clinical Trial 22
6.2 Next Generation Triage CardioProfilER 23
6.2.1 Product Status 23
6.2.2 Product Description 23
6.3 SYNCHRON Anti-Cardiolipin test 24
6.3.1 Product Status 24
6.3.2 Product Description 24
6.4 Vyent NT-proBNP 24
6.4.1 Product Status 24
6.4.2 Product Description 25
6.4.3 Clinical Trial 25
6.5 CADPrint 26
6.5.1 Product Status 26
6.5.2 Product Description 26
6.5.3 Clinical Trial 26
6.6 Key Takeaway 28
7 Appendix 29
7.1 Definitions 29
7.1.1 Cardiac Markers 29
7.2 Research Methodology 30
7.3 Secondary Research 31
7.4 Primary Research 31
7.5 Models 31
7.6 Forecasts 32
7.7 Expert Panels 32
7.8 Consulting 32
7.9 Contact Us 33
7.10 Disclaimer 33
1.1 List of Tables
Table 1: Commonly Used Cardiac Markers, Indications and Reference Range 8
Table 2: Cardiovascular Disease Statistics, US, 2006 9
Table 3: Cardiac Markers, Global, Revenue ($ m), 2000-2008 12
Table 4: Cardiac Markers, Global, Revenue ($ m), 2008-2015 13
Table 5: Novel Cardiac Markers Under Study 16
Table 6: Cardiac Markers, Cross Country Comparison of Revenue-2008 and 2015 18
Table 7: Cardiac Markers Pipeline Products by Development Stage 20
Table 8:ARCHITECT MPO Assay, Product Status 21
Table 9:ARCHITECT MPO Assay, Product Description 21
Table 10:Architect MPO Assay Clinical Trial 22
Table 11:Next Generation Triage CardioProfilER, Product Status 23
Table 12:Next Generation Triage CardioProfilER, Product Description 23
Table 13:SYNCHRON Anti-Cardiolipin test, Product Status 24
Table 14:SYNCHRON Anti-Cardiolipin test, Product Description 24
Table 15:Vyent NT-proBNP, Product Status 24
Table 16:Vyent NT-proBNP, Product Description 25
Table 17:Vyent NT-proBNP, Clinical Trial 25
Table 18:CADPrint, Product Status 26
Table 19:CADPrint, Product Description 26
Table 20:CADPrint, Clinical Trial 26
Table 21: Global Cardiac Markers Pipeline Products Summary 27
1.2 List of Figures
Figure 1: Cardiovascular Disease Statistics, US, 2006 9
Figure 2: Cardiac Markers, Global, Revenue ($ m), 2000-2008 12
Figure 3: Cardiac Markers, Global, Revenue ($ m), 2008-2015 13
Figure 4: Cardiac Markers, Cross Country Comparison of Revenue-2008 and 2015 17
Figure 5: Methodology 30
